Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05961163 Terminated - Stroke Clinical Trials

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures: an Observational Study

CLIMATE
Start date: July 24, 2023
Phase:
Study type: Observational

The CLIMATE Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific efforts, somatosensory amplification, self-efficacy, health literacy and commitment to the GP, degree of urbanisation of the patients' administration district and characteristics of the patients' neighborhood are associated with these effects.

NCT ID: NCT05155020 Terminated - Asthma Clinical Trials

A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

Start date: February 11, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.

NCT ID: NCT05013073 Terminated - Asthma Clinical Trials

ASTHMAXcel Emergency Department Study

ASTHMAXcel
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

This protocol focuses on Phase 1 of a planned two-phase research project. Phase 1 aims to test and adapt a prototype ASTHMAXcelED application for the ED. Phase 2 will be an RCT to test the efficacy of a refined ASTHMAXcelED app after being modified based on the results of Phase 1.

NCT ID: NCT04993443 Terminated - Asthma Clinical Trials

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Start date: September 6, 2021
Phase: Phase 1
Study type: Interventional

This is Phase I first-in-human trial evaluating the safety, tolerability, immunogenicity, and pharmacogenomics of LQ036 via inhalation and IV infusion. The study will be divided into 4 parts: Single Ascending Dose, Multiple Ascending Dose, and Intra Venous with a target of 88 healthy volunteers and 30 patients with mild Asthma.

NCT ID: NCT04987944 Terminated - Asthma Clinical Trials

Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

Start date: October 18, 2021
Phase: Phase 1
Study type: Interventional

This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.

NCT ID: NCT04946318 Terminated - Asthma Clinical Trials

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

Start date: September 8, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or high dose ICS plus LABA alone or with additional asthma controllers (additional controllers allowed: LTRA, LAMA, Theophylline and its derivatives), who have completed the prior phase llb study CCSJ117A12201C (NCT04410523).

NCT ID: NCT04855591 Terminated - Asthma Clinical Trials

A Trial of SHR-1703 in Healthy Subjects

Start date: June 14, 2021
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics and immunogenicity of subcutaneous administered SHR-1703 in healthy subjects.

NCT ID: NCT04847674 Terminated - Asthma Clinical Trials

A Study to Test if TEV-53275 is Effective in Relieving Asthma

Start date: May 4, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of TEV-53275 administered subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic phenotype compared to placebo. A secondary objective is to evaluate the efficacy of TEV-53275 compared to placebo assessed by lung function, asthma symptoms, rescue medication use, and quality of life measures. Another secondary objective is to evaluate the safety and tolerability of TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic phenotype compared with placebo, and lastly, to evaluate the immunogenicity of TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic phenotype.

NCT ID: NCT04705727 Terminated - Asthma in Children Clinical Trials

Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation

ASTHMAFAST
Start date: August 23, 2021
Phase: Phase 3
Study type: Interventional

Combined use of inhaled corticosteroids and long-acting β-agonists (LABAs) as the controller and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma. A recent systematic review supports the combined use of inhaled corticosteroids and LABA as both the controller and quick relief therapy (SMART) among patients aged 12 years. In Emergency room (ER), Meta-analysis showed that using salbutamol (or albuterol) by meter doses inhaler (MDI) with a valved holding chamber (VHC) in children with moderate-severe acute asthma exacerbation was more effective, that is, fewer hospital admissions, more clinical improvement, and had fewer adverse effects (tremor and tachycardia) than salbutamol by nebulizer. Therefore, several international guidelines recommend the use of salbutamol by MDI rather than by nebulizer for moderate-severe asthma exacerbations. In children older than 8 years old, dry-powder inhaler (DPI), a device that delivers medication to the lungs in the form of a dry powder is currently used for maintenance and reliever therapy rather than MDI. In this context, we aim to assess the use of combined inhaled corticosteroids and long-acting β-agonists (LABAs) as a quick relief therapy in children older than 8 years old presenting at the ER with moderate asthma exacerbation. Acute asthma patients who had severe exacerbation were excluded from this study (these patients receiving systematically continuous nebulized salbutamol and/or intravenous salbutamol upon their arrival)

NCT ID: NCT04663386 Terminated - Asthma Clinical Trials

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway

BufoSwitch
Start date: December 10, 2020
Phase:
Study type: Observational

This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.